THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Therapeutic Solutions International, Inc.

TSOI

US8833781011

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 15:18:45 2024-07-15 EDT			5-day change	1st Jan Change
0.00065 ^USD	-7.14%		-22.22%	-30.00%

05-30	Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-17	Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Therapeutic Solutions International, Inc. Announces Distribution Agreement with Smile Cosmetic SARL

January 24, 2013 at 09:00 am

Therapeutic Solutions International, Inc. announced the signing of an agreement with Smile Cosmetic SARL for the distribution of Therapeutic Solutions International's AMPSA products in Morocco.

Latest news about Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-17	CI
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients	03-04	CI
Therapeutic Solutions International, Inc. Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease	12-11	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene	23-10-20	CI
Res Nova Bio Appoints George Delgado to Scientific Advisory Board	23-10-17	CI
Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils	23-09-29	CI
Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board	23-09-18	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Therapeutic Solutions International, Inc. Announces FlorStilbene?? Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer	23-08-21	CI
Allogen Biologics Inc. Successfully Manufactures JadiCell	23-08-16	CI
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene?	23-07-18	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy	23-04-20	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Therapeutic Solutions International, Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Therapeutic Solutions International Advances Chronic Obstructive Pulmonary Disease Program by Identifying Novel B Regulatory Cell Mechanism of Action for Jadicell Universal Donor Adult Stem Cell	23-03-13	CI
Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using Florstilbene Immune Stimulator Through Res Nova Bio Subsidiary	23-03-06	CI
Therapeutic Solutions International Launches Veltmeyer Institute for Advanced Biologics	23-02-21	CI
Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics	22-12-05	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease	22-11-14	CI
Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc	22-10-27	CI
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient	22-10-24	CI

Chart Therapeutic Solutions International, Inc.

Duration

Period

Chart Therapeutic Solutions International, Inc.

More charts

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Medical Devices & Implants

	1st Jan change	Capi.
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.	-30.00%	3.1M
SMITH & NEPHEW PLC	-1.61%	12.12B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-20.75%	6.91B
GLAUKOS CORPORATION	+54.95%	6.72B
INSPIRE MEDICAL SYSTEMS, INC.	-31.88%	4.12B
AXONICS, INC.	+9.03%	3.46B
ENOVIS CORPORATION	-20.14%	2.45B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-19.75%	1.88B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-29.10%	1.57B
DOUBLE MEDICAL TECHNOLOGY INC.	-37.42%	1.45B